ARVN three-lens brief
Evidence-based stock research on ARVN. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Negative free cash flow last quarterly (-$94.50M).
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $13.93 — 60% above current (14 analysts).
- Negative free cash flow last quarterly (-$94.50M).
ARVN closed at $8.71 (-0.57%) as of 2026-09-11. Market cap: $569.51M. P/E (trailing) 33.5. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $13.93 — 60% above current (14 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; negative free cash flow last quarterly (-$94.50M).. Last quarter: Revenue $249.70M, net income $169.40M, free cash flow -$94.50M.
Why three lenses on ARVN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARVNacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ARVN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARVN brief"></iframe>